Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis

By afschroeder • July 27, 2025

Papp KA, Armstrong AW, Koresawa T, Otake K, Hirata M, Kano A. Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis. J Eur Acad Dermatol Venereol. 2025 Jul 25. doi: 10.1111/jdv.20863. Epub ahead of print. PMID: 40715001.

Tags: Dermatology, efficacy, ME3183, phosphodiesterase 4 inhibitor, plaque psoriasis, Publications, randomized controlled study, safety

Bidirectional risk relationship between autoimmune blistering diseases and monoclonal gammopathies: A large-scale matched cohort study

Curman P, Ngo BT, Ludwig RJ, Kasperkiewicz M. Bidirectional risk relationship between autoimmune blistering diseases and monoclonal gammopathies: A large-scale matched cohort study. JAAD Int.[...]

Granulysin-high decidual NK cells in macaques and humans share signatures of immune defense

Prasanphanich NS, Protti G, Cappelletti M, Ma F, Pithia N, Dasenbrock A, Stanek J, Chougnet CA, Kallapur SG, Pellegrini M, Tilburgs T, Presicce P. Granulysin-high[...]

GLP-1RAs and cardiovascular risk reduction in hidradenitis suppurativa: A real-world cohort study

Chou PP, Jeong C, Ma E, Roberts AM, Katz A, Nong Y, Yan MJ, Johnsen N, Armstrong AW. GLP-1RAs and cardiovascular risk reduction in hidradenitis[...]